JP2021521192A - セレブロンリガンドおよび同リガンドを含む二機能性化合物 - Google Patents

セレブロンリガンドおよび同リガンドを含む二機能性化合物 Download PDF

Info

Publication number
JP2021521192A
JP2021521192A JP2020555835A JP2020555835A JP2021521192A JP 2021521192 A JP2021521192 A JP 2021521192A JP 2020555835 A JP2020555835 A JP 2020555835A JP 2020555835 A JP2020555835 A JP 2020555835A JP 2021521192 A JP2021521192 A JP 2021521192A
Authority
JP
Japan
Prior art keywords
alkyl
syndrome
group
optionally substituted
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521192A5 (cg-RX-API-DMAC10.html
Inventor
アンドリュー ピー． クルー，
アンドリュー ピー． クルー，
クレイグ エム． クルーズ，
クレイグ エム． クルーズ，
ハンチン ドン，
ハンチン ドン，
キース アール． ホーンバーガー，
キース アール． ホーンバーガー，
ジン ワン，
ジン ワン，
イミン チアン，
イミン チアン，
カート ジマーマン，
カート ジマーマン，
マイケル バーリン，
マイケル バーリン，
ローレンス ビー． スナイダー，
ローレンス ビー． スナイダー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvinas Operations Inc
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/953,108 external-priority patent/US20180228907A1/en
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of JP2021521192A publication Critical patent/JP2021521192A/ja
Publication of JP2021521192A5 publication Critical patent/JP2021521192A5/ja
Priority to JP2023174374A priority Critical patent/JP7748432B2/ja
Priority to JP2025156045A priority patent/JP2025186428A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
JP2020555835A 2018-04-13 2019-04-09 セレブロンリガンドおよび同リガンドを含む二機能性化合物 Pending JP2021521192A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023174374A JP7748432B2 (ja) 2018-04-13 2023-10-06 セレブロンリガンドおよび同リガンドを含む二機能性化合物
JP2025156045A JP2025186428A (ja) 2018-04-13 2025-09-19 セレブロンリガンドおよび同リガンドを含む二機能性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/953,108 US20180228907A1 (en) 2014-04-14 2018-04-13 Cereblon ligands and bifunctional compounds comprising the same
US15/953,108 2018-04-13
PCT/US2019/026570 WO2019199816A1 (en) 2018-04-13 2019-04-09 Cereblon ligands and bifunctional compounds comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174374A Division JP7748432B2 (ja) 2018-04-13 2023-10-06 セレブロンリガンドおよび同リガンドを含む二機能性化合物

Publications (2)

Publication Number Publication Date
JP2021521192A true JP2021521192A (ja) 2021-08-26
JP2021521192A5 JP2021521192A5 (cg-RX-API-DMAC10.html) 2022-04-18

Family

ID=66248825

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020555835A Pending JP2021521192A (ja) 2018-04-13 2019-04-09 セレブロンリガンドおよび同リガンドを含む二機能性化合物
JP2023174374A Active JP7748432B2 (ja) 2018-04-13 2023-10-06 セレブロンリガンドおよび同リガンドを含む二機能性化合物
JP2025156045A Pending JP2025186428A (ja) 2018-04-13 2025-09-19 セレブロンリガンドおよび同リガンドを含む二機能性化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023174374A Active JP7748432B2 (ja) 2018-04-13 2023-10-06 セレブロンリガンドおよび同リガンドを含む二機能性化合物
JP2025156045A Pending JP2025186428A (ja) 2018-04-13 2025-09-19 セレブロンリガンドおよび同リガンドを含む二機能性化合物

Country Status (9)

Country Link
EP (1) EP3774772A1 (cg-RX-API-DMAC10.html)
JP (3) JP2021521192A (cg-RX-API-DMAC10.html)
KR (1) KR20210003804A (cg-RX-API-DMAC10.html)
CN (2) CN118480030A (cg-RX-API-DMAC10.html)
AU (3) AU2019251223A1 (cg-RX-API-DMAC10.html)
CA (1) CA3095912A1 (cg-RX-API-DMAC10.html)
IL (3) IL302595A (cg-RX-API-DMAC10.html)
MX (2) MX2020010571A (cg-RX-API-DMAC10.html)
WO (1) WO2019199816A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540970A (ja) * 2021-10-22 2024-11-06 シーツァン ハイスコ ファーマスーティカル カンパニー リミテッド Ｐａｒｐ－１分解剤及びその使用
JP2025520909A (ja) * 2022-06-30 2025-07-03 アンホーン メディシンズ カンパニー リミテッド 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法
JP7906859B2 (ja) 2021-10-22 2026-08-18 シーツァン ハイスコ ファーマスーティカル カンパニー リミテッド Ｐａｒｐ－１分解剤及びその使用

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
BR112020023136A2 (pt) 2018-05-14 2021-02-09 Nuvation Bio Inc. compostos de alvo de receptor de hormônio nuclear anticâncer
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
US12186401B2 (en) 2019-03-01 2025-01-07 Ontario Institute for Cancer Research (OICR) and Sinai Health System Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
US11890346B2 (en) * 2019-06-12 2024-02-06 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
WO2021041348A1 (en) * 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP7852923B2 (ja) 2019-11-27 2026-04-28 キャプター セラピューティクス エス．エー． セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法
US20230099031A1 (en) * 2019-12-17 2023-03-30 Orionis Biosciences, Inc. Bifunctional agents for protein recruitment and/or degradation
PH12022551482A1 (en) * 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2021127443A1 (en) * 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP4681715A3 (en) 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
CA3170620A1 (en) * 2020-03-06 2021-09-10 Maoyi LEI Crystal of tricyclic compound acting on crbn protein and preparation method therefor
CN115380026B (zh) * 2020-03-17 2023-11-07 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
CN115605267B (zh) * 2020-03-21 2025-07-29 阿维纳斯企业公司 突变体lrrk2蛋白水解的选择性调节剂和相关使用方法
KR20230004511A (ko) 2020-03-21 2023-01-06 아비나스 오퍼레이션스, 인코포레이티드 인다졸계 화합물 및 관련된 사용 방법
CN113582974B (zh) * 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
WO2021255212A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Braf degraders
CN115916769B (zh) * 2020-06-28 2024-09-10 深圳扬厉医药技术有限公司 并环吲唑类化合物
TW202216684A (zh) * 2020-07-09 2022-05-01 大陸商四川海思科製藥有限公司 用於抑制與降解雄激素受體的化合物、醫藥組合物及其應用
CN114341128B (zh) * 2020-07-24 2024-06-25 恩瑞生物医药科技（上海）有限公司 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
WO2022048605A1 (zh) * 2020-09-04 2022-03-10 南昌奥瑞药业有限公司 一种杂环化合物、其制备方法、中间体、组合物以及应用
CN114262319B (zh) * 2020-12-01 2023-05-05 南昌奥瑞药业有限公司 一类双功能分子、其制备方法及其应用
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
IL303143A (en) * 2020-12-14 2023-07-01 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN112679338A (zh) * 2020-12-28 2021-04-20 丽珠集团新北江制药股份有限公司 一种制备噁唑啉杀虫剂阿福拉纳中间体的方法
CN112707809B (zh) * 2020-12-30 2023-08-29 丽珠集团新北江制药股份有限公司 一种制备噁唑啉杀虫剂氟雷拉纳中间体的方法
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
US12655135B2 (en) 2021-02-04 2026-06-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
CA3211347A1 (en) 2021-03-19 2022-09-22 Erika Araujo Indazole based compounds and associated methods of use
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2024512544A (ja) * 2021-03-29 2024-03-19 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用
CN115141179B (zh) * 2021-03-31 2024-09-13 江苏恒瑞医药股份有限公司 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
WO2022235585A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20240287076A1 (en) 2021-05-05 2024-08-29 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
BR112023024507A2 (pt) 2021-05-26 2024-02-15 C4 Therapeutics Inc Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
US20250129047A1 (en) 2021-07-04 2025-04-24 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2023283372A1 (en) 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
CA3224732A1 (en) 2021-07-07 2023-01-12 Kevin M. Guckian Compounds for targeting degradation of irak4 proteins
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
CN115611909A (zh) * 2021-07-12 2023-01-17 江苏恒瑞医药股份有限公司 四氢萘类化合物、其制备方法及其在医药上的应用
KR20240040769A (ko) * 2021-07-26 2024-03-28 아비나스 오퍼레이션스, 인코포레이티드 이작용성 화합물을 제조하는 방법
WO2023016518A1 (zh) * 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
CN115746058A (zh) * 2021-09-03 2023-03-07 南京知和医药科技有限公司 一种多环化合物在制备抗肿瘤药物方面的用途
JP2024539269A (ja) * 2021-10-22 2024-10-28 グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CN114516810B (zh) * 2022-01-18 2023-12-26 浙江奥翔药业股份有限公司 制备药物中间体2-氨基-4-羟基苯甲酸的方法
CN114085213B (zh) * 2022-01-20 2022-03-25 苏州国匡医药科技有限公司 一种arv-471的制备方法
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
IL316803A (en) 2022-06-06 2025-01-01 C4 Therapeutics Inc Bicyclic glutarimide-modified cervalon-binding agents
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
CA3260847A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen Alpha Receptor Degrading Agents and Their Uses
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
EP4554948A1 (en) * 2022-07-12 2025-05-21 Regents of the University of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2024039210A1 (ko) * 2022-08-17 2024-02-22 한국화학연구원 Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도
CN115403561B (zh) * 2022-08-22 2024-03-08 西安交通大学 一种基于沙利度胺类似物的细胞内自组装蛋白降解剂及其制备方法和应用
US20250388575A1 (en) * 2022-09-08 2025-12-25 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
JP2025533592A (ja) * 2022-09-29 2025-10-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 テトラリン系誘導体の薬学的に許容される塩、結晶型及び調製方法
CN119998300A (zh) * 2022-09-29 2025-05-13 海南先声再明医药股份有限公司 一类稠环化合物及其用途
CN117801051A (zh) * 2022-09-30 2024-04-02 苏州德亘生物医药有限公司 一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
KR20250079173A (ko) 2022-10-03 2025-06-04 고리츠다이가쿠호진 요코하마시리츠다이가쿠 이환성 구조를 갖는 이미다조피리딘 유도체
CN116751186B (zh) * 2022-12-23 2024-10-18 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
CN120615091A (zh) * 2023-01-16 2025-09-09 正大天晴药业集团股份有限公司 取代的苯并七元环化合物及其应用
CN120569372A (zh) 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
CN116253719B (zh) * 2023-03-06 2025-04-01 苏州国匡医药科技有限公司 一种雌激素和雄激素受体双重降解剂及其应用
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs
WO2024226422A1 (en) * 2023-04-22 2024-10-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Helicase degraders
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
CN121263412A (zh) * 2023-06-01 2026-01-02 上海海和药物研究开发股份有限公司 用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物
JP2026524477A (ja) 2023-06-30 2026-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｋｒａｓの分解のためのヘテロ二官能性化合物
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
CN119613374A (zh) * 2023-09-14 2025-03-14 中国科学院上海药物研究所 吲唑酮类化合物、其制备方法、药物组合物及其应用
AU2024352092A1 (en) 2023-09-28 2026-04-09 Arvinas Operations, Inc. Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 ３－苯基丙基胺衍生物
IL327667A (en) * 2023-10-12 2026-06-01 Kolm Therapeutics Inc Bifunctional androgen receptor compounds
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025129172A1 (en) * 2023-12-14 2025-06-19 The Board Of Trustees Of The Leland Stanford Junior University Crbn molecular glue degraders and uses thereof
AU2023477303A1 (en) * 2023-12-22 2026-06-04 Captor Therapeutics S.A. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
WO2025245032A1 (en) * 2024-05-20 2025-11-27 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
WO2026026826A1 (en) * 2024-07-31 2026-02-05 Insilico Medicine Ip Limited Crbn-binding compounds and uses thereof
WO2026060321A1 (en) 2024-09-13 2026-03-19 Olema Pharmaceuticals, Inc. Kat6 degrader compounds and method thereof
GB202414342D0 (en) * 2024-09-30 2024-11-13 Otsuka Pharma Co Ltd Pharmaceutical compounds
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2026138908A1 (zh) * 2024-12-24 2026-07-02 海创药业股份有限公司 一种雌激素受体降解剂中间体及其制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534631A (ja) * 2005-04-07 2008-08-28 天津和美生物技▲術▼有限公司 細胞の腫瘍壊死因子釈放を抑制できるピペリジン−２，６−−ジオン誘導物
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016197032A1 (en) * 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
JP2017513862A (ja) * 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2018052949A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
WO2018052945A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
US20180099940A1 (en) * 2016-10-11 2018-04-12 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2018119448A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
WO2019148055A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
JP2020506914A (ja) * 2017-01-26 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． エストロゲン受容体タンパク質分解性の調節因子およびその関連方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
CA2877434A1 (en) 2012-06-25 2014-01-03 Oncoethix Sa Method of treating lymphoma using thienotriazolodiazepine compounds
CA2901805A1 (en) 2013-02-22 2014-08-28 Bayer Pharma Aktiengesellschaft 4-substituted pyrrolo- and pyrazolo-diazepines
WO2015011084A1 (de) 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428513B2 (en) 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
JP6351306B2 (ja) 2014-03-06 2018-07-04 キヤノン株式会社 画像処理装置、画像処理装置の制御方法およびプログラム
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015195863A1 (en) 2014-06-20 2015-12-23 Constellation Pharmaceuticals, Inc. Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
KR20170055549A (ko) 2014-10-02 2017-05-19 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 화합물
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
IL266842B (en) * 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
EP3634960A1 (en) * 2017-06-09 2020-04-15 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US20210154184A1 (en) * 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN109422733A (zh) * 2017-09-03 2019-03-05 上海美志医药科技有限公司 一类抑制并降解酪氨酸蛋白激酶alk的化合物

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534631A (ja) * 2005-04-07 2008-08-28 天津和美生物技▲術▼有限公司 細胞の腫瘍壊死因子釈放を抑制できるピペリジン−２，６−−ジオン誘導物
JP2017513862A (ja) * 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016197032A1 (en) * 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2018052949A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
WO2018052945A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
US20180099940A1 (en) * 2016-10-11 2018-04-12 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2018119448A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
JP2020504741A (ja) * 2016-12-23 2020-02-13 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
JP2020506914A (ja) * 2017-01-26 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
WO2019148055A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
JP2021512153A (ja) * 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540970A (ja) * 2021-10-22 2024-11-06 シーツァン ハイスコ ファーマスーティカル カンパニー リミテッド Ｐａｒｐ－１分解剤及びその使用
JP7906859B2 (ja) 2021-10-22 2026-08-18 シーツァン ハイスコ ファーマスーティカル カンパニー リミテッド Ｐａｒｐ－１分解剤及びその使用
JP2025520909A (ja) * 2022-06-30 2025-07-03 アンホーン メディシンズ カンパニー リミテッド 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法
JP2025524557A (ja) * 2022-06-30 2025-07-30 アンホーン メディシンズ カンパニー リミテッド 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法

Also Published As

Publication number Publication date
CA3095912A1 (en) 2019-10-17
MX2023002134A (es) 2023-03-16
IL277934A (en) 2020-11-30
CN112262134A (zh) 2021-01-22
IL310860A (en) 2024-04-01
IL302595A (en) 2023-07-01
AU2025275145A1 (en) 2026-01-08
AU2023248067B2 (en) 2025-09-04
JP7748432B2 (ja) 2025-10-02
KR20210003804A (ko) 2021-01-12
WO2019199816A1 (en) 2019-10-17
EP3774772A1 (en) 2021-02-17
CN112262134B (zh) 2024-05-24
MX2020010571A (es) 2021-01-08
AU2023248067A1 (en) 2023-11-02
JP2023175957A (ja) 2023-12-12
JP2025186428A (ja) 2025-12-23
CN118480030A (zh) 2024-08-13
AU2019251223A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
JP7748432B2 (ja) セレブロンリガンドおよび同リガンドを含む二機能性化合物
US12239711B2 (en) Cereblon ligands and bifunctional compounds comprising the same
JP7824261B2 (ja) セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
JP7679173B2 (ja) Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
JP6778114B2 (ja) イミド系タンパク質分解モジュレーター及び関連する使用方法
JP6873433B2 (ja) タンパク質分解のイミド系修飾因子および関連の使用方法
JP2021073251A (ja) 標的タンパク質の分解向上のための化合物および方法
JP2021169481A (ja) アンドロゲン受容体の標的分解のための化合物および方法
CN117279910A (zh) Bcl6蛋白水解的调节剂和其相关使用方法
CN108137507A (zh) 基于mdm2的蛋白水解调节剂和相关的使用方法
JP2020506922A5 (cg-RX-API-DMAC10.html)
JP2020505327A (ja) Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
KR20180029061A (ko) 단백질 분해의 알라닌계 조절인자 및 관련된 이용 방법
RU2830173C2 (ru) Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы
RU2795146C2 (ru) Лиганды цереблона и бифункциональные соединения, содержащие их
CN118574827A (zh) Brm靶向化合物和相关的使用方法
HK1232864A1 (en) Imide-based modulators of proteolysis and associated methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231130